Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02992951
Other study ID # R2034
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 19, 2017
Est. completion date January 1, 2025

Study information

Verified date March 2024
Source Hull University Teaching Hospitals NHS Trust
Contact Ross Lathan, MBChB
Phone 01482674643
Email ross.lathan2@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgical site infection is an infection at a place in the body where surgery has taken place, and has been reported in around 5% of people undergoing an operation. In vascular surgery, infection rates are as high as 30%. Methods to reduce this rate of infection should be investigated thoroughly for their effectiveness and cost-effectiveness. The investigators aim to conduct a research trial examining one such method. Leukomed Sorbact is a wound dressing coated with a chemical (DACC) derived from spider-silk that interacts with, and binds bacteria, causing them to be mechanically removed from a wound when the dressing is changed. The trial aims to compare the effectiveness of this dressing to a standard, non-coated dressing, in the reduction of surgical site infection. 718 patients from a number of centres across the UK will be recruited to this study. Adult patients who are having a vascular surgery operation will be approached for entry into the trial. The trial will be explained to them, as well as an explanation that participation is voluntary and their operation or other aspects of their care will not be impacted in any way should participants not wish to participate. Participants will be randomised by computer into one of two groups - one group whose wounds are dressed with Leukomed Sorbact, and the other whose wounds are dressed with a standard dressing. Patients will be followed up at 30 days post-operatively. At the follow up, their wounds will be inspected for infection, and participants will be asked to complete short questionnaires measuring quality of life. Quality of life will also be assessed at 3 months post surgery. The trial will aim to answer a number of questions, with the primary question being does a DACC coated dressing applied after an operation reduce the risk of an infection at the surgery site? It will also ask whether this treatment is cost-effective and whether it promotes satisfactory healing and evaluate the overall carbon footprint impact of each intervention. Studies Within a Trial will be conducted to validate a remote diagnostic measure for detecting surgical site infection using wound images and the Bluebelle Wound Healing Questionnaire, evaluate feasibility of novel hair removal methods such as epilation and waxing, carbon footprint modelling within randomised controlled trials.


Recruitment information / eligibility

Status Recruiting
Enrollment 718
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: In order to be eligible for inclusion in the study the participants must meet the following criteria: - Adults =18 yrs undergoing clean or clean-contaminated lower limb vascular surgery, with wounds closed by primary intention. - Able to understand the Patient Information Sheet and supplementary materials and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits and completing written questionnaires). Exclusion Criteria: Patients will not be included in the study if they meet any of the following exclusion criteria: - Patients on antibiotics for other conditions at the time of surgery or in the follow up period. - Patients undergoing any procedure that does not include lower limb incisions. - Allergies to any component of either the DACC-coated dressing or the control dressing. - Inability to give informed consent due to incapacity (as defined by the MCA 2005) - Aged under 18 years at the time of recruitment - Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study.

Study Design


Intervention

Device:
DACC-Coated Post Operative Dressing
Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.

Locations

Country Name City State
United Kingdom Academic Vascular Surgery Unit, Vascular Laboratory, Alderson House, Hull Royal Infirmary Hull East Riding Of Yorkshire

Sponsors (2)

Lead Sponsor Collaborator
Hull University Teaching Hospitals NHS Trust University of Hull

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Totty JP, Harwood AE, Cai PL, Hitchman LH, Smith GE, Chetter IC. Assessing the effectiveness of dialkylcarbamoylchloride (DACC)-coated post-operative dressings versus standard care in the prevention of surgical site infection in clean or clean-contaminated, vascular surgery (the DRESSINg trial): study protocol for a pilot feasibility randomised controlled trial. Pilot Feasibility Stud. 2019 Jan 18;5:11. doi: 10.1186/s40814-019-0400-2. eCollection 2019. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other SWAT 1 Validation Acceptability Response rates to measure at 30 and 37 days 30 and 37 days
Other SWAT 1 Validation reliability Inter and intra rater reliability 30 and 37 days
Other SWAT 1 Validation Validity Sensitivity, specificity, ROC analysis, AUC 30 days
Other SWAT 2 Hair Removal Feasibility Safety/adverse events 30 days
Other Carbon Footprint Model Development Healthcare resource use data, consumable item weights 3 months
Primary 30 day infection rate Surgical Site Infection at 30 days post-op 30 days
Secondary 3 month infection rate Surgical Site Infection at 3 months post-op (implant patients only) 3 months
Secondary Quality of Life (SF-36 V2) Score ranging from 0-100, higher values indicating better health 30 days, 3 months
Secondary Quality of Life (EQ-5D-3L) Score ranging from 5-15, higher scores indicating worse health 30 days, 3 months
Secondary Mortality 30-day mortality 30 days
Secondary Bluebelle wound healing questionnaire Score ranging 0-41, higher values indicating infection Days 30 and 37
Secondary Carbon Footprint Analysis Healthcare resource use data 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT02905955 - Vacuumtherapy After Venous Hybrid Procedures Phase 4
Not yet recruiting NCT02868372 - Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine N/A
Enrolling by invitation NCT02559453 - Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds N/A
Completed NCT02744144 - Wound Bacterial Microbiota and Their Antibiotic Resistance N/A
Active, not recruiting NCT01939145 - Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation Phase 4
Completed NCT00998907 - PDS*Plus and Wound Infections After Laparotomy N/A
Completed NCT01141335 - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair Phase 4
Completed NCT00576745 - A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery Phase 1
Terminated NCT00654641 - Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy N/A
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Recruiting NCT00150852 - Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus. Phase 2
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT04596124 - Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze N/A
Active, not recruiting NCT04584957 - Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.) N/A
Recruiting NCT03960970 - Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries Phase 2
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT02018094 - The Amputation Surgical Site Infection Trial (ASSIT) Phase 4
Terminated NCT03269968 - Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery N/A
Enrolling by invitation NCT02945761 - High Concentration of Sugar Solution Irrigation Promotes the Healing of Infected Wound N/A
Not yet recruiting NCT02882360 - Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum Phase 4

External Links